

respiratoryMEDICINE

Volume 96, 2002

HARCOURT PUBLISHERS LTD
London · Philadelphia · Sydney · Tokyo · Toronto

Copyright © 2002 Harcourt Publishers Ltd

ALL RIGHTS RESERVED

No part of this volume may be reproduced in any form,
by photostat, microfilm, or any other means, without
written permission from the publishers

Index

(E) indicates Editorial; (CR) indicates Case Report; (L) indicates Letter to the editors; (R) indicates Report; (SR) indicates Short Report; (TR) indicates Topical Review

- α 1-antitrypsin Pi phenotypes S and Z in Spain: an analysis of the published surveys (TR) 109–114
 Aalbers, R. 404–407
 Aalto, E. 949–955
 Abal, A. T. 548–552
 Abe, S. 943–948
 Åberg, H. 22–30
 Abu-Ekteish, F. 766–767
 ACE gene polymorphism and cough threshold for capsaicin after cilazapril usage 130–135
 adenosine 5' monophosphate, airway sensitivity, relationship to shape of the concentration-response curve to methacholine in subjects with allergic rhinitis 457–463
 adrenaline-Pirquet test compared with international PPD tuberculin tests 205–211
 Aessopos, A. 471–475
 Aguilar, J. J. 975–979
 Agustí, C. 822–828
 Ahlner, J. 670–675
 AIDS-related *Pneumocystis carinii* pneumonia associated with bronchoalveolar lavage neutrophilia, independent risk of mechanical ventilation for 661–669
 Aiello, M. 986–991
 airway function, apparent response to deep inspiration 251–257
 Akashiba, T. 393–397
 Akkaya, E. 666–675
 Alasali, K. 341–347
 Alatas, F. 829–835
 Albuquerque, J. P. jr 281–286
 Alcock P. 147–152
 Aldenbratt, A. 153–158
 Al-Hedaithy, S. S. A. 341–347
 Alldred, A. 965–968
 Allegra, L. (TR) 95–108
 allergens: sensitization and exposure to pet allergens in asthmatics versus non-asthmatics with allergic rhinitis 122–129
 allergic bronchopulmonary mycosis in asthma patients 341–347
 allergic rhinitis, relationship between airway sensitivity to adenosine 5' monophosphate and the shape of the concentration-response curve to methacholine in subjects with 457–463
 allergies: three-year follow-up study of workers in a mushroom factory 943–948
 allergy, respiratory: a follow-up study of 99 patients up to 10 years 9–12
 Al-Majed, S. 341–347
 almitine and medroxyprogesterone acetate: effect on arterial blood gases in chronic obstructive pulmonary disease 602–605
 Al-Mobeireek, A. F. 341–347
 Alpers, J. H. 437–443
 Altuntas, N. 237–239
 Alving, K. 153–158
 Ambrosino, N. 246–250, 520–525, 539–547
 Amin, K. 904–910
 Andersson, B. 40–47, 363–373
 Andersson, F. 505–512
 Angus, K. 265–274
 Ankerst, J. 484–490
 Annala, I. 949–955
 antibiotic choice, guiding principles S20
 antibiotic therapy, re-evaluating current S12
 Armstrong, G. R. 374–378
 Arroliga, A. C. 305–309
 Arvidsson, P. 313–318, 535
 Arzani, D. 430–432
 Asano, T. 577–581
 asbestos- and erionite-induced Turkish malignant pleural mesothelioma, ras oncoprotein expression in (SR) 697–698
 asbestos exposure, environmental: p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with epidemiological features and prognosis of mesotheliomas with 588–593
 asthma: airway responsiveness as a direct factor contributing to dyspnoea perception 464–470
 :allergic bronchopulmonary mycosis in asthma patients 341–347
 :analysis of montelukast in mild persistent asthmatic patients with near-normal lung function 379–386
 :and allergies associated with wood stoves 911–916
 :and gastro-oesophageal reflux: can the response to anti-reflux therapy be predicted? 387–392
 :and reflexology 173–179
 :budenoside but not nedocromil reduces exhaled nitric oxide levels in asthmatic children 734–739
 :changes in drug therapy costs for patients receiving chronic montelukast therapy in the U.K. 83–89
 :clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 μ g twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild to moderate asthma 136–146

- :comparison between formoterol 12 µg b.i.d. and on-demand salbutamol in moderate persistent asthma 64–70
- :comparison of costs in patients starting fluticasone propionate compared to patients starting montelukast 227–234, 627
- :comparison of lung deposition of budesonide from Easyhaler^(R), Turbuhaler^(R) and pMDI plus spacer in asthmatic patients 720–727
- :compositional and functional changes of pulmonary surfactant in a guinea-pig model 180–186
- :cost analysis of the use of inhaled corticosteroids 992–998
- :cost-effectiveness study comparing the as-needed use of formoterol (Oxis^(R)) and terbutaline (Bricanyl^(R)) 753–758
- :education (E) 849–850
- :effect of different concentrations of lactose powder on airway function of adult asthmatics 870–875
- :efficacy of HFA-beclomethasone dipropionate extra-fine aerosol (800 µg day⁻¹) versus HFA-fluticasone propionate (1000 µg day⁻¹) 212–220
- :eosinophil cationic protein in saliva: new marker of disease activity in bronchial asthma 670–675
- :formoterol added to budesonide in moderate asthma – health economic results from the FACET study 505–512
- :granulocyte markers in induced sputum in patients with respiratory disorders and healthy persons obtained by two sputum-processing methods 48–55
- :history and future of treating asthma as a systemic and small airways disease 703–719
- :importance of the device S26–S29
- :incidence of physician-diagnosed asthma in adults: real incidence or a result of increased awareness? 685–692
- :increased level of bronchial responsiveness in inactive children with asthma 806–810
- :leisure-time energy expenditure in asthmatics and non-asthmatics 13–18
- :long-acting bronchodilators in premenstrual exacerbation 740–743
- :long-term economic evaluation of intensive patient education during the first treatment year in newly-diagnosed adult asthma 56–63
- :measuring control in group studies: do we need airway calibre and rescue β₂-agonist use? 319–323
- :possible doping effect of inhaled β₂-agonist formoterol upon endurance performance in healthy well-trained athletes 571–576
- :psychological disorder associated with poor control and poor adherence to inhaled steroids 37–39
- :quality of life in primary care asthma 22–30
- :relevance of dyspnoea and respiratory function measurements in monitoring 251–257
- :role of nurse in treatment compliance and self-management following hospital admission 851–856
- :total nitrite/nitrate in expired breath condensate of patients 649–654
- :using a revised morbidity index to identify varying patterns of morbidity in UK general practice (SC) 1006–1011
- :sensitization and exposure to pet allergens in asthmatics versus non-asthmatics with allergic rhinitis 122–129
- asthma, allergic: secular trends in Danish adults 258–264
- asthma, chronic bronchitis and respiratory symptoms among adults in Estonia according to a postal questionnaire 954–964
- Ates H. 844–845
- Aubier, M. 212–220
- Azzolin, N. 734–739
- β₂-agonists – from pharmacological properties to everyday clinical practice S1
- :clinical outcome of addition to inhaled corticosteroids S12–S16
- :evolution S2–S6
- :pharmacological similarities and differences S7–S11
- Bacakoglu, F. 844–845
- Bacon, R. E. 720–727
- Bake, B. 40–47, 363–373
- Bando, M. 935–942
- Bang, D. 661–669
- Baraldi, E. 754–739
- Baran, A. 802–805
- Baran, R. 666–675
- Barnes, N. 379–386
- Barnes, P. J. 505–512, 1003–1005, S12–S16
- Basoglu, O. K. 844–845
- Basta, M. 841–843
- Bateman, E. D. 136–146
- Battistini, A. 986–991
- Bayramgürler, B. 666–675
- Beder, S. 811–816
- Bende, M. 19–21
- Benfield, T. L. 661–669
- Bengsun, S. 811–816
- Bengtsson, P. 744–752
- Benhamou, D. 817–821
- Ben-Joseph, R. H. 83–89
- Bennani, I. 331–335
- benzalkonium chloride as a preservative in nasal solutions 728–733
- Berar-Yanay, N. 740–743
- Berggren, F. 753–758
- Berglund, L. 773–767
- Beviacqua, M. 243–245
- Bianchi, L. 246–250, 520–525
- Biernacki, W. A. 1003–1005

- Bindels, P. J. E. 496–504
Bjerner, L. 122–129, 703–719
Björnsson, E. 891–897, 904–910
Blanco, I. 109–114
Blasi, F. 95–108
Blomberg, A. 491–495
Boğa, S. 802–85
Bogolubov, M. 136–146
Boijesen, M. 363–373
Boman, G. 904–910
Bordenave, R. H. 243–245
Borgström, L. 534, S26–S29
Boschetto, P. 357–362
Botelho, M. A. M. 281–286
Bottema, B. J. A. 496–504
Bourcereau, J. 64–70
Bourdeix, I. 64–70, 817–821
Bousquet, J. 799–801
bradykinin challenge, local: exudation of plasma and production of thromboxane in human bronchi after 313–318
Bratel, T. 676–684
Brightling, C. E. 999–1002
bronchiectatic airways, macrophages, neutrophils and tumour necrosis factor- α expression *in vivo* 792–798
bronchitis, chronic: four week trial with inhaled steroids does not attenuate airway inflammation 115–121
brucellosis, presenting solely as pneumonia, (CR) 766–767
Brygge, T. 173–179
budenoside: and nedocromil sodium, effect on IL-6 and IL-8 release from human nasal mucosa and polyp epithelial cells 408–414
 :comparison of lung deposition from Easyhaler^(R), Turbuhaler^(R) and pMDI plus spacer in asthmatic patients 720–727
 :formoterol added to, in moderate asthma – health economic results from the FACET study 505–512
 :inhaled from Easyhaler^(R) and from Turbuhaler^(R), systemic effects in healthy male volunteers 863–869
budenoside but not nedocromil reduces exhaled nitric oxide levels in asthmatic children 734–739
budenoside therapy, inhaled, effect on lung function in schoolchildren born preterm 565–570
budesonide inhalations: effects on diffusing capacity and ventilation-perfusion relationships in chronic obstructive pulmonary disease 676–684
Burnell, P. K. P. 324–330
Burns, G. P. 251–257
Ca 125, evaluation of tuberculosis activity 666–675
Califano, C. 917–921
Campbell, C. A. 147–152
Canonica, G. W. 9–12
capsaicin after cilazapril usage, ACE gene polymorphism and cough threshold for 130–135
capsaicin cough sensitivity is decreased in smokers 19–21; (L) 768
carbon dioxide monitoring: is continuous transcutaneous monitoring of $P\text{CO}_2$ (TcPCO_2) over 8 h reliable in adults? 331–335
carbon monoxide, exhaled, in patients with lower respiratory tract infection 1003–1005
Carboni, I. 430–432
Carlsen, K.-H. 571–576, 806–810, 898–903
Carrà, S. 734–739
Carrión, M. 822–282
Cars, O. S20
Castagnaro, A. 969–979
Cazzola, M. (TR) 95–108; 917–921
CCR2 and CCR5 gene polymorphism in children with recurrent respiratory infections (SC) 430–432
Çelik, L. 237–239
Chan, C.-C. 297–304
Chan, S.-P. 297–304
Chanez, P. 799–801
Chappell, S. E. 612–617
Charpin, D. 922–923
Chen, Y. 13–18
Cheng, G. 180–186
Cherian, J. 548–552
Chetta, A. 969–979, 986–991
Chitano, P. 357–362
Chlamydia pneumoniae infection and acute exacerbation of chronic obstructive pulmonary disease 811–816
Choi, I. S. 464–470
Choi, S. J. 594–601
chronic obstructive airways disease, accuracy of pulse oximeters in patients with acute exacerbations of 336–340
chronic obstructive pulmonary disease: a qualitative exploration of the experience of patients in Leeds 196–204
 :added value of co-morbidity in predicting health-related quality of life 496–504
 :body weight-walking distance product as related to lung function, anaerobic threshold and peak VO_2 618–626
 :changes in inflammatory markers following treatment of acute exacerbations of 891–897
 :*Chlamydia pneumoniae* infection and acute exacerbation of 811–816
 :combined inhalation of nitric oxide and oxygen in patients with moderate to severe COPD: effect on blood gases 927–934
 :comparison of three disease-specific and two generic health-status measures to evaluate the outcome of pulmonary rehabilitation in 71–77
 :DiskusTM and TurbuhalerTM inhalers, *ex-vivo* product performance using inhalation profiles from patients with severe COPD 324–330

- :does the mode of inhalation affect the bronchodilator response? 476–483
- :effect of almitine and medroxyprogesterone acetate on arterial blood gases in 602–605
- :effects on diffusing capacity and ventilation-perfusion relationships of budesonide inhalations 676–684
- :erythropoietic response to hypoxaemia in diffuse idiopathic pulmonary fibrosis, as opposed to 471–475
- :Formoterol Turbuhaler^(R) for as-needed therapy in patients with mild acute exacerbations of 917–921
- :granulocyte markers in induced sputum in patients with respiratory disorders and healthy persons obtained by two sputum-processing methods 48–55
- :hospital re-admission in patients with acute exacerbation 876–884
- :induced sputum and other outcome measures, safety and repeatability 999–1002
- :long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation 448–456
- :perception of disability among patients applying for pension 398–403
- :rapid onset of bronchodilation, a placebo-controlled study comparing formoterol (Foradil^(R) AerolizerTM) with salbutamol (VentodiskTM) 817–821
- :review of long-term oxygen therapy 437–443
- :role of domiciliary nebulizers in managing patients with severe COPD 265–274
- :sexuality in chronic respiratory failure: coincidences and divergences between patient and primary caregiver 975–979
- Chrystyn, H. 965–968
- Churg-Strauss syndrome, sputum eosinophilia in 799–801
- cilazapril usage, ACE gene polymorphism and cough threshold for capsaicin after 130–135
- Ciprandi, G. 9–12
- clarithromycin, oral, efficacy and safety compared to oral moxifloxacin regimens in the treatment of community-acquired pneumonia 553–564
- Clini, E. 520–525
- clinical failures: the tip of the iceberg? 55
- Cluley, S. 37–39
- Cobben, N. A. M. 781–786
- coccidioidomycosis in non-endemic areas 305–309
- Cochrane, G. M. 37–39
- Collins, P. 173–179
- Combe, P. 857–862
- common variable immunodeficiency: respiratory disorders in 191–195
- community-acquired lower respiratory tract infections, quantitative culture of bronchoalveolar lavage fluid in 885–890
- community-acquired pneumonia: efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of 553–564
- Compte-Torrero, L. 191–195
- computer program supporting the diagnostic accuracy of cellular BALF analysis: a new release 781–786
- Corbo, G. M. 430–432
- Corda, L. 520–525
- Corrado, O. J. 965–968
- corticosteroids, inhaled; cost analysis in the treatment of asthma 992–998
- Costabel, U. 781–786
- Craig, W. A. S2, S12
- Cramer, D. 526–531
- Cranston, J. M. 437–443
- Cremona, G. 520–525
- Crockett, A. J. 437–443
- Cuvelier, A. 817–821
- cyclodextrin as a potential drug carrier in sambutamol dry powder aerosols: the *in-vitro* deposition and toxicity studies of the complexes 513–519
- cystic fibrosis: inspiratory muscle training in patients with 31–36
- :*Pseudomonas aeruginosa* in: cross-infection and the need for segregation 147–152
- :six-minute walking test in adults with mild to moderate lung disease 986–991
- cytokines in pleural liquid for diagnosis of tuberculous pleurisy 577–581
- D'Amato, G. 917–921
- D'Amato, M. 917–921
- D'Ippolito, R. 969–979
- Dahl, R. 167, 773–767
- Dahlén, I. 891–897
- Dales, R. 13–18
- Daskalogiannaki, 841–843
- Davies, P. D. O. 435–436
- Davies, R. J. O. 594–601
- de Jong, W. 31–36
- De Marzo, N. 357–362
- de Muralto, B. 331–335
- de Rojas, F. 191–195
- De Vries, J. (L) 159
- Dekker, F. W. 496–504
- Demedts, M. 3348–356
- Demircan, S. 588–593
- Desai, S. A. 305–309
- Di Perna, 917–921
- diffuse idiopathic pulmonary fibrosis: erythropoietic response to hypoxaemia in, as opposed to chronic obstructive pulmonary disease 471–475
- Dirksen, A. 258–264
- Diskus^(R) and Turbuhaler^(R), equivalent therapeutic ratio of salbutamol given by 534–535
- DiskusTM and TurbuhalerTM inhalers, *ex-vivo* product performance using inhalation profiles from patients with severe chronic obstructive pulmonary disease 324–330
- Doig, S. 324–330

- domiciliary nebulizers: role in managing patients with severe COPD 265–274
- Drent, M. (L) 159; 781–786
- Duchenne's muscular dystrophy, lung function in children with 898–903
- Duranti, R. 246–250
- Duroux, P. 64–70
- Durucu, M. 802–805
- Dutau, H. 922–923
- dyspnoea: and respiratory function measurements relevance in monitoring asthma 251–257
:measurement and treatment (TR) 539–547
- earlobe arterialized capillary blood, clinical utility in assessment of patients for long-term oxygen therapy 655–660
- Easyhaler^(R), Turbuhaler^(R) and pMDI plus spacer: comparison of lung deposition of budesonide from in asthmatic patients 720–727
- Easyhaler^(R) and Turbuhaler^(R), systemic effects of budesonide in healthy male volunteers inhaled from 863–869
- Eaton, T. 655–660
- Eaton, T. E. 582–587
- Ece, F. 666–675
- Edelman, J. M. 379–386
- Egan, J. J. 787–791
- Ehrs, P. O. 22–30
- Eide, G. E. 205–211
- Eiser, N. 265–274, 476–483
- Ekberg-Jansson, A. 40–47, 363–373
- Ekman, A. 153–158, 491–495
- Ekström, T. 753–758
- Elkjær, J. 661–669
- Elliott, A. 744–752
- El-Rab, M. O. Gad. 341–347
- Emborg, J. 661–669
- Emri, S. 697–698
- Emte, S. 844–845
- Enander, I. 363–373
- environment and socio-economic group: relation to prevalence of obstructive lung diseases and respiratory symptoms 744–752
- eosinophil cationic protein in saliva: new marker of disease activity in bronchial asthma 670–675
- eosinophilic pneumonia, acute, with increased soluble ST2 in serum and bronchoalveolar lavage fluid (CR) 532–533
- eosinophils and respiratory medicine 168–169
- eosinophils in induced sputum from asymptomatic smokers with normal lung function 969–979
- Epstein-Barr virus and wild p53 in idiopathic pulmonary fibrosis 787–791
- Erginel, S. 829–835
- Ersay, Y. 237–239
- Ertugrul, D. 697–698
- Escarrabill, J. 975–979
- Estonia: asthma, chronic bronchitis and respiratory symptoms among adults according to a postal questionnaire 954–964
- Etemadi, A. 444–447
- ethnic differences in anthropometry among adult Singaporean Chinese, Malays and Indians, and their effects on lung volumes 297–304
- Everard, M. L. 275–280
- exocytosis, regulated, in immune function: are SNARE proteins involved? (TR) 773–780
- Fabbri, L. M. 357–362
- Faber, C. E. 631–638, 639–648
- Fabra, J. M. 408–414
- Faggian, D. 357–362
- Farrero, 975–979
- Fernández, E. (TR) 109–114
- fibre-optic bronchoscopy: influence of patient posture on oxygen saturation during 5–8
- Firat, P. 697–698
- flextube reflectometry: for determination of sites of upper airway narrowing in sleeping obstructive sleep apnoea patients 639–648
:for localization of upper airway narrowing – a preliminary study in models and awake subjects 631–638
- flu-like illness, recurrent, with migrating pulmonary infiltrates of unknown aetiology 348–356
- fluticasone propionate: comparison of costs in asthma patients compared to patients starting montelukast 227–234
- fluticasone propionate hydrofluoroalkane pressurised metered dose inhalers: dose proportionality of and comparability with chlorofluorocarbon pMDIS (L) 160–163
- Foglio, K. 246–250
- Font, A. 975–979
- Foresi, A. 969–979, 986–991
- formoterol: 12 µg b.i.d. compared with on-demand salbutamol in moderate persistent asthma 64–70
:added to budesonide in moderate – : health economic results from the FACET study 505–512
:(Foradil^(R) AerolizerTM) compared with salbutamol (VentodiskTM) in a placebo-controlled study of rapid onset of bronchodilation in chronic obstructive pulmonary disease: 817–821
:Turbuhaler^(R) for as-needed therapy in patients with mild acute exacerbations of COPD 917
:possible doping effect upon endurance performance in healthy well-trained athletes 571–576
:(Oxis^(R)) and terbutaline (Bricanyl^(R)) cost-effectiveness study comparing as-needed use in patients with moderate to severe asthma 753–758
:safety issues S21–S25
:used as needed – clinical effectiveness S17–S20
:where does it fit current guidelines? S30–S34

- Formoterol and Corticosteroids Establishing Therapy (FACET) 505–512
- Franklin, K. A. 423–429
- Frolund, L. 258–264
- Fuentes, M. 408–414
- Fukuda, T. 180–186
- Furuya, K. 130–135
- Gagliardi, L. 734–739
- Ganas, K. 649–654
- Gans, S. J. M. 212–220
- Garau, J. S5
- Gargioni, S. 9–12
- Garrett, J. E. 582–587, 655–660
- gastro-oesophageal reflux, and asthma: can the response to anti-reflux therapy be predicted? 387–392
- Gehrchen, P. M. 173–179
- Gibbs, A. R. 588–593, 829–835
- Gibson, G. J. 251–257, 324–330
- Gigliotti, F. 246–250
- glaucoma associated with metred-dose bronchodilator therapy (L) 844–845
- glucocorticoids, inhaled, compliance with and concomitant use of long-acting β_2 -agonists 404–407
- Gonis, A. 187–190
- Gordon, S. M. 305–309
- Gouitaa, M. 922–923
- Graf, P. 728–733
- Granader, M. 863–869
- Grange, J. M. 444–447
- Grassi, V. 520–525
- Gray, J. 147–152, 1006–1011
- Grazzini, M. 246–2250
- Green, R. H. 999–1002
- Grey, C. 582–587
- Griffis, D. L. 992–998
- Grymer, L. 631–638, 639–648
- Grzincich, G. L. 986–991
- Gudbjörnsson, B. 904–910
- Gulsvik, A. 205–211
- Gungen, Y. 697–698
- Guthrie, S. J. 196–204
- Gutiérrez, V. 457–463
- Haatela, T. 48–55
- Hack, M. A. 594–601
- Hadzistavrou, C. 471–475
- haemoptysis: aetiology, evaluation and outcome – a prospective study in a third world country 548–552
- Hagihara, S.-I. 532–533
- Hakonen, T. 949–955
- Hakulinen, A. L. 565–570
- Hallman, M. 565–570
- Hämäläinen, K. M. 863–869
- Hanson, I. M. 374–378
- Hargreaves, C. 1006–1011
- Harmanci, E. 588–593, 829–835
- Hart, N. 526–531
- Hasleton, P. S. 787–791
- Heegard, S. 173–179
- Heinig, J. H. 173–179
- Held, T. 571–576
- Helenius, H. 387–392, 911–916
- Helleday, R. 491–495
- Hem, E. 571–576
- Henriksen, A. H. 122–129
- Herland, K. 571–576
- Hernández, M. D. 191–195
- Herrmann, F. R. 415–422
- HFA-beclomethasone dipropionate extra-fine aerosol ($800 \mu\text{g day}^{-1}$), efficacy versus HFA-fluticasone propionate ($1000 \mu\text{g day}^{-1}$) 212–220
- HFA-fluticasone propionate ($1000 \mu\text{g day}^{-1}$), efficacy versus of HFA-beclomethasone dipropionate extra-fine aerosol ($800 \mu\text{g day}^{-1}$) 212–220
- Hietanen, E. 387–392
- Hilberg, O. 631–638, 639–648
- Hilden, J. 173–179
- Hill, K. M. 196–204
- Hirst, P. H. 720–727
- histamine bronchial testing in young males, short-term repeatability 287–291
- Hoeffken, G. 553–564
- Hoffman, H. J. 773–767
- Holmen, T. L. 122–129
- Horie, T. 393–397
- Hosoda, M. 577–581
- Hrabec, E. 1–4
- Hrabec, Z. 1–4
- hyatid disease, complicated pulmonary, pitfalls in diagnosis (SR) 237–239
- Hyland, M. E. 71–77
- hypercalcaemia in Greek patients with tuberculosis before the initiation of anti-tuberculosis treatment 187–190
- Ianni, A. 430–432
- Ibáñez, M. 975–979
- idiopathic pulmonary fibrosis: Epstein-Barr virus and wild p53 in 787–791
- :infection of TT virus in patients with 935–942
- Ijzermans, C. J. 496–504
- Ilias, I. 187–190
- Imai, K. 943–948
- In-Check Meter^(R), measurement of peak inhalation rates to identify an elderly person's ability to use a Turbuhaler^(R) 965–968
- inspiratory muscle trainer in healthy humans, an evaluation (R) 526–531
- inspiratory muscle training in patients with cystic fibrosis 31–36

- integrins, expression in human cultured mesothelial cells:
 roles in cell-to-extracellular matrix adhesion and inhibition by RGD-containing peptide 221–226
- Isik, R. 588–593
- Işıksoy, S. 588–593
- Ito, D. 393–397
- Itoh, M. 577–581
- Jacobs, J. A. 781–786
- Jannus-Pruljan, L. 954–964
- Janson, C. 891–897, 904–910
- Janssens, J. P. 331–335, 415–422
- Jasani, B. 588–593
- Jenkins, R. 324–330
- Jensen, F. T. 639–648
- Jentoft, H. J. 205–211
- Johansson, A. 484–490
- Joharjy, I. 341–347
- Jones, A. M. 374–378
- Jones, K. 1006–1011
- Jönsson, E. 685–692, 954–964
- Jørgensen, T. 258–264
- Jörres, R. A. 115–121, 927–934
- Jouhikainen, T. 949–955
- Jovine, L. 357–362
- Jungersten, L. 153–158
- Juniper, E. F. 319–323
- Kakish, K. 766–767
- Kalogeropoulos, N. 649–654
- Kanneiss, F. 115–121, 927–934
- Karnak, D. 811–816
- Kasielski, M. 448–456
- Kato, T. 532–533, 577–581
- Kauppinen, R. 56–63
- Kava, T. (SR) 90–91
- Kawakami, Y. 130–135
- Kayacan, O. 811–816
- Kazi, D. 187–190
- Kelly, A.-M. 336–340
- Kelly, B. G. 787–791
- Kharitonov, S. A. 1003–1005
- Kilian, M. 885–890
- Kiliçoglu, G. 237–239
- Kiljander, T. 387–392
- Kilpeläinen, M. 911–916
- Kiviloog, J. 954–964
- Klaukka, T. 56–63
- Klugman, K. SI
- Koba, H. 943–948
- Koëter, G. H. 31–36
- Koh, Y. I. 464–470
- Konstantopoulos, K. 471–475
- Kontos, A. 471–475
- Korsgaard, J. 885–890
- Kosaka, N. 393–397
- Koskenvuo, M. 911–916
- Kottakis, J. 817–821
- Kraan, J. 31–36
- Krewski, D. 13–18
- Kuo, S.-H. 221–226
- Kuroiwa, K. 532–533
- lactose powder, effect of different concentrations on airway function of adult asthmatics 870–875
- Ladosky, W. 281–286
- Lagerstrand, L. 676–684
- Lagogianni, I. 187–190
- Lam, W. K. 792–798
- Lamers, R. J. S. 292–296
- Lammers, J. W. J. 235–236
- Lan, N. N. 444–447
- Lange, P. 980–985
- Larsson, K. 22–30, 685–692
- Larsson, L.-G. 423–429
- Lau, A. C.-W. 876–884
- Laurent, F. 857–862
- Le Gros, V. 64–70, 817–821
- Leclerc, V. 817–821
- Ledin, M.-C. 491–495
- Lee, Y.-C. 221–226
- Leff, J. A. 379–386
- Lenney, W. 147–152, 170–172
- Leung, R. 792–798
- Leynadier, F. 64–70
- Liaw, Y.-S. 221–226
- Liippo, K. 387–392, 949–955
- Lim, H. 464–470
- Lindberg, A. 423–429
- Lindholm, L. H. 744–752
- Linneberg, A. 258–264
- Lipworth, B. J. (L) 160–161
- Ljungkvist, G. 491–495, G. 153–158
- Lodrup Carlsen, K. C. 898–903
- Löfdahl, C.-G. 40–47, 313–318, 363–373, 505–512, 744–752
- Loit, H.-M. 954–964
- Lok, S. S. 787–791
- Lombardi, C. 9–12
- Loppow, D. 115–121
- Lötvall, J. 313–318, 535, S7–S11
- Loukides, S. 649–654
- lower respiratory tract infections: critical evaluation of guidelines for treatment of bacterial infections (TR) 95–108
- Lúdviksdóttir, D. 904–910
- Luh, K.-T. 221–226
- Lukkari-Lax, 949–955
- Lundbäck, B. 423–429, 685–692, 954–964
- Lundgren, J. D. 661–669
- lung cancer: in vitro secretion of cytokines and prostaglandin-E₂ by monocytes from lung cancer patients 243

- :elevated level of circulating matrix metalloproteinase-9 in patients with I-4
 :induced sputum in diagnosis not visible endoscopically 822-828
 :prophylactic cranial irradiation in limited disease small-cell lung cancer in complete remission (SR) 235-236
 :value and accuracy of cytology in addition to histology in diagnosis at flexible bronchoscopy 374-378
 Lydakakis, C. 841-843
- Maakel, M. L. 799-801
 Macián, V. 191-195
 Maderal, M. A. 975-979
 Madsen, F. (L) 160; 258-264
 Magadle, R. 740-743
 Magnussen, H. 115-121, 927-934
 Majore, S. 430-432
 Malerba, M. 520-525
 Malinen, A. 863-869
 Malmström, M. 670-675
 Malorgio, R. 969-979
 Mapp, C. E. 357
 Marangio, E. 969-979
 Marín, J. 457-463
 Marshall, M. 5-8
 Martínez García, M. A. 191-195
 Matera, M. G. 917-921
 matrix metalloproteinase-9, circulating, elevated level in patients with lung cancer I-4
 Matsuura, 943-948
 Mauskopf, J. 227-234
 McGivern, D. V. 5-8
 McHale, S. 265-274
 McLaughlin, T. 227-234, 992-998
 meconium aspiration injury: comparison of surfactant delivery with conventional mechanical ventilation and partial liquid ventilation in, 612-617
 medroxyprogesterone acetate and almitine: effect on arterial blood gases in chronic obstructive pulmonary disease 602-605
 Meghjee, S. P. L. 5-8
 Meren, M. 954-964
 mesothelioma, diffuse malignant pleural: prognostic factors 829-835
 mesothelioma, Turkish malignant pleural, erionite- and asbestos induced, ras oncoprotein expression in (SR) 697-698
 mesotheliomas with environmental asbestos exposure, p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with epidemiological features and prognosis of 588-593
 methacholine, shape of the concentration-response curve, relationship between airway sensitivity to adenosine 5' monophosphate in subjects with allergic rhinitis 457-463
 Metintas, M. 588-593, 829-835
 Metintas, S. 588-593, 829-835
 Metso, T. 48-55
 Meyer, H. P. 553-564
 Meziane, H. 799-801
 Michel, J. P. 415-422
 Miller, M. R. 287-291
 Millqvist, E. 19-21
 Milner, A. D. 275-280
 Minai, O. A. 305-309
 Molimard, M. 64-70
 Möller, J. K. 885-890
 monocytes from lung cancer patients, in vitro secretion of cytokines and prostaglandin-E₂ by 243-245
 montelukast: analysis in mild persistent asthmatic patients with near-normal lung function 379-386
 :changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K. 83-89
 :comparison of costs in asthma patients starting fluticasone propionate compared to patients starting 227-234, 627
 Monterio, VV. 999-1002
 Montnèmy, P. 744-752
 Montón, C. 822-828
 Morgan, M. D. L. 71-77, 999-1002
 Morice, A. 851-856
 Moss, J. R. 437-443
 Mowinkel, P. 571-576
 Moxham, J. 526-531
 moxifloxacin regimens, oral, efficacy and safety compared to oral clarithromycin in the treatment of community-acquired pneumonia 553-564
 Muers, M. F. 196-204
 Muir, J. F. 817-821
 Mulder, P. G. H. 781-786
 Mullol, J. 408-414
 Muñoz Pamplona, M. P. 191-195
Mycobacterium vaccae, heat-killed, in treatment of multi-drug-resistant pulmonary tuberculosis 444-447
 N-acetylcysteine, long-term administration decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease 448-456
 Nair, P. C. 548-552
 Nakamura, A. 577-581
 Nauffal Manzur, M. D. 191-195
 nedocromil: budesonide but not nedocromil reduces exhaled nitric oxide levels in asthmatic children 734-739
 nedocromil sodium and budesonide, effect on IL-6 and IL-8 release from human nasal mucosa and polyp epithelial cells 408-414
 Nemery, B. 348-356
 Nettelbladt, O. 904-910
 Newman, S. P. 720-727

- Nguyen, M. C. 415–422
Nicholson, F. H. G. 836–840
Nielsen, L. P. 773–767
Nielsen, N. H. 258–264
Nieminen, M. M. 949–955
nitric oxide, exhaled, in patients with PiZZ phenotype-related α 1-anti-trypsin deficiency 520–525
nitric oxide, increased, in exhaled air after intake of a nitrate-rich meal 153–158
nitric oxide and oxygen, combined inhalation in patients with moderate to severe COPD: effect on blood gases 927–934
nitric oxide in exhaled air after experimental ozone exposure in humans 491–495
nitric oxide levels, exhaled, reduced by budesonide but not nedocromil in asthmatic children 734–739
nitrite/nitrate in expired breath condensate of asthma patients 649–654
Nolard, N. 348–356
Norregaard, O. 631–638, 639–648
Nowak, D. 448–456
Nsour, W. M. 965–968
Nyberg, P. 744–752
Nystad, W. 806–810

O'Byrne, P. M. 319–323, 505–512
O'Driscoll, B. R. 374–378
O'Neil, B. 305–309
obesity: chest mechanics in morbidly obese non-hypoventilated patients 281–286
obstructive sleep apnoea: effects compared with sleep deprivation and alcohol on simulated steering performance 594–601
:flextube reflectometry for determination of sites of upper airway narrowing in sleeping patients 639–648
:optimal continuous positive airway pressure: role of craniofacial structure 393–397
:prevalence of daytime hypercapnia or hypoxia (SR) 693–698
:related symptoms are common in subjects with asthma, chronic bronchitis and rhinitis in a general population (R) 423–429
Ohno, S. 935–942
Okamoto, H. 935–942
Olin, A.-C. 153–158, 491–495
Olivieri, D. 969–979, 986–991
Olut, A. 697–698
Omenaas, E. 205–211
Omeland, Ø. 287–291
Öner, Ü. 588–593
Ooi, G. C. 792–798
Orehek, J. 602–605
Oshikawa, K. 532–533, 935–942
Oxis^(R), protection against cold air and exercise-induced bronchoconstriction while on regular treatment with 484–490
oxygen saturation: influence of patient posture during fibre-optic bronchoscopy 5–8
oxygen therapy: long term, for chronic obstructive pulmonary disease 437–443
:long-term: arterialized earlobe capillary blood, clinical utility in assessment of patients for 655–660
:non-continuous home: utilization, symptomatic effect and prognosis 980–985
:short-term: the prescription of oxygen to patients with chronic lung disease hypoxic at discharge from hospital 582–587
ozone exposure in humans, experimental, nitric oxide in exhaled air after 491–495
Özvaran, K. 237–239

p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure 588–593
Palmqvist, M. 484–490, 535
Panagou, P. 649–654
Pantin, C. 147–152
Papatheodorou, P. 649–654
Parker, D. 999–1002
Partridge, J. S. L. (SR) 90–91
Partridge, M. R. (SR) 90–91
Pasaoglu, O. 829–835
Pasquis, P. 693–698
Passalacqua, G. 9–12
patient education, intensive, long-term economic evaluation during the first treatment year in newly-diagnosed adult asthma 56–63
Patsopoulos, D. 187–190
Pauwels, R. A. 505–512, S30–S34, S1
Pavord, I. D. 999–1002
Pedersen, O. F. 287–291
Pelkonen, A. S. 565–570
Pérez, M. 408–414
Perpiñá Tordera, M. 191–195
Perrin, E. 331–335
Persson, G. 484–490
Petersen, I. L. 898–903
Peterson, C. 48–55
Peterson, C. G. B. 891–897
pets: sensitization and exposure to pet allergens in asthmatics versus non-asthmatics with allergic rhinitis 122–129
Philippou, N. 187–190
Phillips, C. 476–483
Picado, C. 408–414
Picaud, C. 331–335
Piebani, M. 357–362
Pinet, C. 602–605
Pini, L. 520–525
Pisi, G. 986–991

- Pitcairn, G. R. 720–727
- PIZZ phenotype-related $\alpha 1$ -anti-trypsin deficiency, exhaled nitric oxide in patients with 520–525
- pleural effusion, invisible, on standard postero-anterior X-ray (CR) 922–923
- Pneumocystis carinii* pneumonia, AIDS-related, associated with bronchoalveolar lavage neutrophilia, independent risk of mechanical ventilation for 661–669
- pneumonia as the sole presentation of brucellosis (CR) 766–767
- pneumonia, community acquired, influence of severity on usefulness of blood cultures 78–82
- Polkey, M. I. 526–531
- Pölluste, J. 954–964
- Poluman, A. 802–805
- Poole, M. D. SI
- Poon, E. 876–844
- Postma, D. S. 505–512
- post-pneumonic empyema, delayed referral reduces the success of video-assisted thorascopic debridement for 836–840
- Poulsen, L. K. 173–179
- Prats, E. 975–979
- premenstrual exacerbation of – : long acting bronchodilators 740–743
- pressurised metered dose inhalers: fluticasone propionate hydrofluoroalkane: dose proportionality and comparability with chlorofluorocarbon pMDIS (L) 160–163
- Price, D. B. 83–89
- Prieto, L. 457–463
- prophylactic cranial irradiation in limited disease small-cell lung cancer in complete remission (SR) 235–236
- Pseudomonas aeruginosa* in cystic fibrosis: cross-infection and the need for segregation 147–152
- psychological disorder in asthma is associated with poor control and poor adherence to inhaled steroids 37–39
- Pujols, L. 408–414
- pulmonary rehabilitation: comparison of three disease-specific and two generic health-status measures to evaluate the outcome of in chronic obstructive pulmonary disease 71–77
- pulse oximeters, accuracy in patients with acute exacerbations of chronic obstructive airways disease 336–340
- quality of life and health-related quality of life measures (L) 159, 160
- Rabe, K. F. 521–525
- Radaeli, A. 520–525
- Raherison, C. 857–862
- Rajesh, P. B. 836–840
- Rasmussen, T. R. 885–890
- Ravel, T. 602–605
- Reanmongkol, 513–519
- Redfern, E. J. 5–8
- reflexology: and bronchial asthma 173–179
- Reiss, T. F. 379–386
- Rengarajan, A. 836–840
- respiratory impedance measurements, diagnostic value in elderly subjects 415–422
- respiratory symptoms relate to physiological changes and inflammatory markers reflecting central but not peripheral airways 40–47
- respiratory syncytial virus: role for prevention 170–172
- ribavirin: effect on previously healthy infants admitted with acute bronchiolitis on acute and chronic respiratory morbidity 275–280
- Ricciardolo, F. 520–525
- Rigby, A. S. 275–280
- Ringbæk, T. 398–403, 980–985
- Roberts, J. M. 319–323
- Roca-Ferrer, J. 408–414
- Rodríguez Roisin, R. 822–828
- Romano-Spica, V. 430–432
- Ronborg, S. 173–179
- Rönmark, E. 685–692
- Roomans, G. M. 904–910
- Rooney, M. (SR) 90–91
- Rosengren, A. 363–373
- Rosi, E. 246–250
- Roussos, A. R. 187–190
- Rudkin, S. 655–660
- Rumi, L. S. 243–245
- Rytilä, P. 48–55
- Saikai, T. 943–948
- Saito, O. 393–397
- salbutamol: dry powder aerosols, cyclodextrin as a potential drug carrier in: the *in-vitro* deposition and toxicity studies of the complexes 513–519
- :given by Turbuhaler^(R) and Diskus^(R), equivalent therapeutic ratio of 534–535
- :metered-dose powder inhaler compared with two other inhaler devices, 949–955
- :on-demand, compared with formoterol 12 μ g b.i.d. and in moderate persistent asthma 64–70
- :(VentodiskTM) compared with formoterol (Foradil^(R) AerolizerTM) in a placebo-controlled study of rapid onset of bronchodilation in chronic obstructive pulmonary disease: 817–821
- salmeterol/fluticasone propionate in combination (50/100 μ g twice daily), clinical equivalence when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild to moderate asthma 136–146
- Salomaa, E.-R. 387–392
- Sandek, K. 676–684
- Sandström, T. 491–495, 685–692, 870–875
- Scano, G. 246–250, 539–547

- Schaaning, J. 484–490
Schadé, E. 496–504
Schiza, S. 841–843
Schleiss, M. B. 115–121
Schlösser, N. J. J. 235–236
Schmekel, B. 670–675
Schwabe, G. 484–490
Scollo, M. 734–739
Scordamaglia, A. 9–12
Sears, M. R. S2–S6
Selroos, O. S17–S20
Senna, G. 9–12
Senol, T. 237–239
Seppälä, O.-P. 949–955
Sevéus, L. 904–910
sexuality in chronic respiratory failure: coincidences and divergences between patient and primary caregiver 975–979
Shaffer, T. H. 612–617
Shingo, S. 379–386
Shukla, A. 773–767
Shum, I. H. 792–798
Shun, C.-T. 221–226
Siafakas, N. M. 841–843
Sigsgaard, T. 287–291
Silins, V. 136–146
Silvasti, M. 720–727
Singh, S. J. 71–77
Sjögren's syndrome, primary, inflammation and structural changes in the airways of patients with 904–910
Skoogh, B.-E. 40–47, 313–318, 363–373
Small, T. 324–330
smoking: neutrophil-associated activation markers in healthy smokers relates to a fall in DL_{CO} and to emphysematous changes on high resolution CT 363–372
SNARE proteins: are they involved with regulated exocytosis in immune function? (TR) 773–780
socio-economic group and living environment: relation to prevalence of obstructive lung diseases and respiratory symptoms 744–752
Sodergren, S. C. 71–77
Solé, M. 822–828
Soler, N. 822–828
Sommer, T. 885–890
spontaneous pneumothorax: pragmatic management and long-term outcome 857–862
:thorascopically-defined idiopathic, diagnostic yield of computed tomography and densitometric measurements of the lung in 292–296
sputum, induced: granulocyte markers in patients with respiratory disorders and healthy persons obtained by two sputum-processing methods 48–55
Srichana, T. 513–519
Stahl, E. 505–512
Stålenheim, G. 891–897
Stanford, C. A. 444–447
Stanford, J. L. 444–447
Stanford, R. H. 227–234, 992–998
Stempel, D. A. 227–234, 992–998
Stendardi, L. 246–250
Stenfors, N. 491–495
Stensrud, T. 571–576
steroid tablets, time of day taken by patients (SR) 90–91
Stewart, J. P. 787–791
Stigum, H. 806–810
Stradling, J. R. 594–601
Strek, M. 1–4
Struikmans, H. 235–236
Suedee, R. 513–519
Sugawara, H. 943–948
Sugiyama, K. 180–186
Sugiyama, Y. 532–533, 935–942
Sulu, E. 802–805
Swarbrick, A. 275–280
Sylvester, K. 526–531
Takahashi, M. 935–942
Takahashi, T. 130–135
Takeya, I. 943–948
Tanaka, H. 943–948
Tangsrud, S. E. 898–903
Tardif, C. 693–698
Tassiopoulos, S. 471–475
Tassiopoulos, T. 471–475
Tattersfield, A. E. 505–512
Taube, C. 115–121
Taytard, A. 857–862
Tel, N. 829–835
ten Velde, G. P. M. 292–296
terbutaline (Bricanyl^(R)) and formoterol (Oxis^(R)) cost-effectiveness study comparing as-needed use in patients with moderate to severe asthma 753–758
Terho, E. O. 387–392, 911–916
Tessonier, F. 602–605
Thoren, P. 870–875
thromboxane production and exudation of plasma in human bronchi after local bradykinin challenge 313–318
Tipoe, G. L. 792–798
Titelion, V. 331–335
Toda, M. 180–186
Toivanen, P. 863–869
Tokunaga, T. 532–533
toluene diisocyanate (TDI), serum-mediated relaxant response in an isolated guinea-pig bronch 357–362
Tominaga, S.-I. 532–533
Tonegawa, K. 577–581
Tor, M. 237–239
Torén, K. 153–158, 491–495
Trejo, Y. G. 243–245
Tsang, K. W. 792–798
Tsunematsu, K. 943–948

- TTvirus, infection in patients with idiopathic pulmonary fibrosis 935-942
- Tubbs, D. 147-152
- tuberculosis: activity, value of Ca 125 in evaluation 666-675
- :hypercalcaemia in Greek patients before the initiation of anti-tuberculosis treatment 187-190
- :multi-drug-resistant (E) 435-436
- :multi-drug-resistant: treatment with heat-killed *Mycobacterium vaccae* 444-447
- :multi-focal, with multiple intracranial tuberculomas in a non-immunocompromised patient (CR) 841-843
- :pulmonary, smear-positive, delays in the diagnosis and treatment of hospitalized patients with 802-805
- Tukiainen, H. 56-63
- Tunon de Lara, J.-M. 857-862
- Turbuhaler^(R), Easyhaler^(R) and pMDI plus spacer: comparison of lung deposition of budesonide from in asthmatic patients 720-727
- :and Diskus^(R), equivalent therapeutic ratio of salbutamol given by 534-535
- :and DiskusTM inhalers, *ex-vivo* product performance using inhalation profiles from patients with severe chronic obstructive pulmonary disease 324-330
- :and Easyhaler^(R) systemic effects of budesonide in healthy male volunteers inhaled from 863-869
- :measurement of peak inhalation rates with an In-Check Meter^(R) to identify an elderly person's ability to use 965-968
- Turki, E. 922-923
- Turpeinen, M. 565-570
- Tylén, U. 363-373
- Ucgun, I. 829-835
- Ueda, T. 180-186
- Ullman, A. 505-512
- Unwin, D. 1006-1011
- Vachier, I. 799-801
- Vaiopoulos, G. 471-475
- Valtysdottir, S. 904-910
- van Aalderen, W. M. C. 31-36
- van Belle, A. F. 292-296
- Van Bleyenbergh, P. 348-356
- van der Linden, Y. M. 235-236
- van der Schans, C. P. 31-36
- van der Tweel, I. 235-236
- van der Woude, H. J. 404-407
- van der Zee, J. S. 496-504
- van Kempen, M. L. 235-236
- van Manen, 496-504
- Vanderschueren, R. G. J. R. A. 235-236
- Venge, P. 168-169, 363-373, 670-675, 891-897, 904-910
- Verhoef, L. 553-564
- Verin, E. 693-698
- Vernejoux, J.-M. 857-862
- Vijayapalan, P. 594-601
- Vilkka, V. 56-63
- Villanueva, P. 857-862
- Vilsvik, J. 484-490
- Viskum, K. 398-403, 980-985
- Waller, D. A. 836-840
- Wallin, A. 870-875
- Wang, Y.-T. 297-304
- Ward, M. J. 849-850
- Ward, S. 526-531
- Wardlaw, A. J. 999-1002
- Waterer, G. W. 78-82
- Wei, L. X. 379-386
- Weiner, P. 740-743
- Wettenger, R. 212-220
- Whitehead, P. J. 870-875
- Wiedemann, H. P. 305-309
- Williams, J. 71-77
- Winter, J. 553-564
- Wolfson, M. R. 612-617
- Wood stove heating, asthma and allergies 911-916
- Wooler, P. A. 476-483
- Wouters, E. F. M. 292-296, 781-786
- Wrench, C. 851-856
- Wunderink, R. G. 78-82
- Xaubet, A. 408-414, 822-828
- Yam, L. Y.C. 876-844
- Yamada, Y. 577-581
- Yamaguchi, E. 130-135
- Yamamoto, H. 393-397
- Yang, P. C. 221-226
- Yap, W.-S. 297-304
- Yazdani, C. 227-234
- Yilmaz, A. 666-675, 802-805
- Yilmaz, D. 802-805
- Yu, C. 379-386
- Yu, C.-J. 221-226
- Zacchello, F. 734-739
- Zanconato, S. 734-739
- Zanini, A. 986-991
- Zhang, Q. 83-89
- Zheng, L. 792-798

Acknowledgements

The Editors of *Respiratory Medicine* would like to thank the following referees for their work in 2001:

- | | | | |
|------------------|-------------------|---------------------|-------------------------|
| R. Aalbers | E. Fink Eriksen | A. Kok-Jensen | H. Permin |
| C. Agusti | P. Faurschou | J. Korsgaard | V. Petrovitz |
| H. Almer | I. M. Ferreira | M. Friis König | H. Pilegaard |
| K. Alving | E. Florvaag | A. Knox | P. Plascke |
| N. Ambrosino | A. Foresi | B. Larsen | L. K. Poulsen |
| H. Arendrup | J. Frederiksen | S. Larsson | P. Prandoni |
| P. Arvidsson | L. Frolund | L. Laursen | D. Price |
| U. Baandrup | J. Fujita | W. Lenney | F. Rasmussen |
| V. Backer | R. Fuller | M. Levy | P. J. Rees |
| P. Bartsch | F. Gallefoss | A. Lindén | P. Revsbech |
| E. Bateman | J. Gibson | B. Lindgren | T. Riis Rasmussen |
| J. H. Baumer | S. Gillett | S. A. Little | R. Rodriguez-Roisin |
| H. Bergstrand | P. Godard | H. Lode | J. Rooyackers |
| J. Boe | S. G. Gordon | C.-G. Löfdahl | P. H. Ryttilä |
| G. Boman | M. Greenblat | J. Lötvall | T. Schaberg |
| D. Bouros | N. Gregersen | O. Löwhagen | A. M. W. I. Schols |
| V. Brusasco | R. Grönneberg | S. Lyager | H. Schonheyder |
| S. Burge | A. Grove | W. MacNee | B. Shapiro |
| P. Camus | P. Gustavsson | F. Madsen | N. M. Siafakas |
| K.-H. Carlsen | T. Hajiro | H. Torp Madsen | T. Sigsgaard |
| A. Cartier | H. E. Hansen | K. Mattson | U. Soes-Petersen |
| M. Cazzola | G. Hedenstierna | A. McConnell | A. Sorriärvi |
| E. Christensen | H. Hedenström | S. Merran | J. Sorli |
| G. Christensen | J. Heinig | N. Milman | P. Sterk |
| H. Chrystyn | J. Henriksen | J. Möller | K. Ström |
| A. Chuchalin | O. Hilberg | M. Morgan | M. Sullivan |
| H. Clausen | G. Hillerdal | A. Morice | J. Sundell |
| M. Cochrane | F. Hirsch | H. Mosbech | A. Szczeklik |
| U. Costabel | A. Hjalmarsen | L. Mosekilde | W. C. Tan |
| I. Cotgreave | W. L. Ho | J. Müller-Quernheim | E. Taudorf |
| D. Cramer | H. J. Hoffmann | A. Munck | J. Thuesen |
| D. Crockcroft | R. Hubbard | N. Mygind | S. Thirstrup |
| B. Dahlén | N. Højby | C. Naspitz | P. Toft |
| S.-E. Dahlén | A. Host | H. Krämer Nielsen | E. Tonnesen |
| P. Davies | B. Brock Jacobsen | L. P. Nielsen | P. Tonnesen |
| R. S. Dijkhuizen | C. Janson | M. Nieminen | C. S. Ulrik |
| A. Dirksen | C. Jansson | O. Norregaard | J. G. van den Aardweg |
| B. Disse | P. Jeffery | D. Nowak | M. P. Rutten-van Mölken |
| R. Djukanovic | E. J. Jensen | N. Obel | J. Vestbo |
| M. J. Doherty | P. K. A. Jensen | C. Olgart | E. Von Mutius |
| E. Dupont | M. John | E. Omenaas | J. Weeke |
| M. Dossing | G. Jonasson | L. Osman | O. Widström |
| J. Efthimiou | G. Jonasson | B. Østergaard | P. Wollmer |
| P. O. Ehrh | P. Jones | K. Østerlind | A. Woodcock |
| M. Elliott | E. Kindt | K. Ostermann | M. Yamaya |
| E. Emtner | V. Kinnula | T. Palshoff | O. Zetterström |
| D. Enarson | J. Kips | M. Partridge | N.-S. Zhong |
| C. -P. Engström | C. Koch | O. F. Pedersen | |



